title: A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone. The Collaborative Study Group for the Treatment of Leprosy in Zaire.
abstract: The cure rates of two treatment regimens in PB leprosy were compared in a prospective randomized trial: treatment U consisting of a single dose of rifampicin 40 mg/K bodyweight, and treatment A of rifampicin 1500 mg in a single dose, followed by one year of daily dapsone 100 mg. In patients with a BI = 0, the cure rates evaluated on the basis of histopathology of skin biopsies, were identical for the two regimens but in patients with a BI = 1, cure and relapse rates were unacceptable. For this reason and particularly the need to separate patients on the basis of the BI in skin biopsies, the single dose regimen does not appear to be suited for wide-scale application.
authors.affiliation: University of Antwerp, Belgium.
authors.forename: S R
authors.initials: SR
authors.lastname: Pattyn
authors.forename: G
authors.initials: G
authors.lastname: Groenen
authors.forename: L
authors.initials: L
authors.lastname: Janssens
authors.forename: L
authors.initials: L
authors.lastname: Kuykens
authors.forename: L B
authors.initials: LB
authors.lastname: Mputu
mesh_terms: D003622:Dapsone / Q000008:administration & dosage*; D015023:Democratic Republic of the Congo; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage*; D012867:Skin / Q000473:pathology
chemical_list: D003622:Dapsone; D012293:Rifampin